Results 221 to 230 of about 515,448 (335)

Clinical Safety of Extended Interval Dosing of Nivolumab in Patients with Melanoma

Clinical Pharmacology &Therapeutics, EarlyView.
Extended interval dosing regimens of immune checkpoint inhibitors have been implemented widely. However, their approval was mainly based on pharmacokinetic modeling and simulations. Consequently, comparative safety data of extended interval dosing regimens in a real‐world setting are limited.
Ruben Malmberg, Maaike M. Hofman, Fatima Ashad, Alaa Daloul, Stefani Oosterveld, Edwin A. Basak, Esther Oomen‐de Hoop, Astrid A. M. van der Veldt, Arjen Joosse, Roelof W. F. van Leeuwen, Ron H. J. Mathijssen   +10 more
wiley   +1 more source

Comparing the genetic and serum expression of LL-37 Antimicrobial Peptide in pemphigus vulgaris and pemphigus foliaceus patients. [PDF]

An Bras Dermatol
Dhaffouli F, Elloumi N, Sellami K, Bahloul E, Tahri S, Turki H, Hachicha H, Abida O.   +7 more
europepmc   +1 more source

Straight to Phase III: Model‐Informed Approach Speeds Depemokimab Clinical Development in Interleukin‐5‐Driven Diseases

Clinical Pharmacology &Therapeutics, EarlyView.
Straight to Phase III: Model‐informed approach speeds depemokimab clinical development in interleukin‐5‐driven diseases. IL‐5, a key mediator of type 2 inflammation, underlies various diseases, including severe asthma, CRSwNP, EGPA, and HES. Reduction in blood eosinophil count (BEC), a biomarker of IL‐5 activity, is commonly used to evaluate the ...
Chiara Zecchin, Stein Schalkwijk, Isabelle J. Pouliquen, Alienor Berges, Nicholas Bird, Richard Follows, Daren Austin   +6 more
wiley   +1 more source

Intracranial manifestations of adult Rosai-Dorfman disease: a systematic review and IPD meta-analysis of 327 cases. [PDF]

Acta Neurochir (Wien)
Perez-Chadid DA, Azmi A, Wijaya JH, Oshinowo T, Avila-Madrigal JP, Gorthy AS, Lakshman Akkineni SS, Egladyous A, Novakovic N, Vojnic M, Sherman JH, Nanda A.   +11 more
europepmc   +1 more source

Gut microbiota‐related modulation of immune mechanisms in post‐infarction remodelling and heart failure

ESC Heart Failure, Volume 12, Issue 2, Page 942-954, April 2025.
Abstract The immune system has long been recognized as a key driver in the progression of heart failure (HF). However, clinical trials targeting immune effectors have consistently failed to improve patient outcome across different HF aetiologies. The activation of the immune system in HF is complex, involving a broad network of pro‐inflammatory and ...
Johann Roessler, Friederike Zimmermann, Bettina Heidecker, Ulf Landmesser, Arash Haghikia   +4 more
wiley   +1 more source

Ciclosporin as upfront therapy in Subcutaneous Panniculitis-like T-cell Lymphoma with aggressive features and in uncomplicated disease: Two case reports and literature review. [PDF]

Clin Hematol Int
Tan BKJ, Ong KH, Ho YH, Chong LL, Gallardo CA.   +4 more
europepmc   +1 more source

Current management of children with acute otitis media: a feasibility survey for a pragmatic study [PDF]

, 2019
Beller, Elaine M., Del Mar, Christopher B., McCullough, Amanda R., Pitoyo, Yupitri, Ranakusuma, Respati W., Safitri, Eka D., Widyaningsih, Ade   +6 more
core   +1 more source

Clinical Efficacy and Patient Reported Impacts of Roflumilast Foam 0.3% in Seborrheic Dermatitis: An Analysis of STRATUM Data for Patients Unresponsive or Intolerant to Topical Corticosteroids

David H. Chu, Brett Stephenson, Jeff Lee, Breyanne Bannister, Conor Hickey, Tracy Westley, Matthew Zirwas   +6 more
openalex   +2 more sources

Topical Corticosteroids

Journal of the Royal College of Physicians of London, 1987
M W, Greaves, R J, Hay
openaire   +2 more sources

Growth differentiation factor‐15 and N‐terminal pro‐BNP in acute heart failure with preserved ejection fraction

ESC Heart Failure, Volume 12, Issue 2, Page 888-899, April 2025.
Abstract Aims Heart failure with preserved ejection fraction (HFpEF) continues to be an increasingly common health problem associated with a high mortality rate. Elevated levels of Growth differentiation factor‐15 (GDF15) and N‐terminal pro‐brain natriuretic peptide (NT‐proBNP) are reportedly associated with poor clinical outcomes in a broad range of ...
Yoichiro Otaki, Tetsu Watanabe, Mari Shimizu, Shingo Tachibana, Junya Sato, Yuta Kobayashi, Harutoshi Tamura, Shigehiko Kato, Satoshi Nishiyama, Hiroki Takahashi, Takanori Arimoto, Masafumi Watanabe   +11 more
wiley   +1 more source